|
rs7903146
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Cumulative epidemiological evidence of an association was graded as strong for rs7903146 [odds ratio (OR) = 1.05, p = 4.13 × 10<sup>-5</sup> ] and rs7904519 (OR = 1.07, p = 2.02 × 10<sup>-14</sup> ) in breast cancer, rs11196172 (OR = 1.11, p = 2.22 × 10<sup>-16</sup> ), rs12241008 (OR = 1.13, p = 1.36 × 10<sup>-10</sup> ) and rs10506868 (OR = 1.10, p = 3.98 × 10<sup>-9</sup> ) in colorectal cancer, rs7086803 in lung cancer (OR = 1.30, p = 3.54 × 10<sup>-18</sup> ) and rs11196067 (OR = 1.18, p = 3.59 × 10<sup>-13</sup> ) in glioma, moderate for rs12255372 (OR = 1.12, p = 2.52 × 10<sup>-4</sup> ) in breast cancer and weak for rs7903146 (OR = 1.11, p = 0.007) in colorectal cancer.
|
28949031 |
2018 |
|
rs7903146
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Three T2D associated risk variants were individually associated with breast cancer risk after adjustment for multiple comparisons using the Bonferroni method (at p < 0.001), rs9939609 (FTO) (OR 0.94, 95 % CI = 0.92-0.95, p = 4.13E-13), rs7903146 (TCF7L2) (OR 1.04, 95 % CI = 1.02-1.06, p = 1.26E-05), and rs8042680 (PRC1) (OR 0.97, 95 % CI = 0.95-0.99, p = 8.05E-04).
|
27053251 |
2016 |
|
rs7903146
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Our results suggest that TCF7L2 polymorphisms rs1225404 and rs7003146, but not rs7903146, may affect breast cancer risk in Northwest Chinese women.
|
27738320 |
2016 |
|
rs7903146
|
|
|
0.060 |
GeneticVariation |
BEFREE |
This meta-analysis demonstrated that TCF7L2 gene polymorphisms (rs12255372 and rs7903146) are associated with an increased susceptibility to breast cancer.
|
25867435 |
2015 |
|
rs7903146
|
|
|
0.060 |
GeneticVariation |
BEFREE |
In conclusion, our findings suggest that rs7903146 (T) variant may elevate the risk of breast cancer, thus could be a potential candidate for breast cancer susceptibility.
|
21301999 |
2012 |
|
rs7903146
|
|
|
0.060 |
GeneticVariation |
BEFREE |
After adjusting for multiple comparisons, four TCF7L2 SNPs were significantly associated with breast cancer overall: rs7903146 (OR(TT) 1.24; 95 % CI 1.03-1.49), rs3750805 (OR(AT/TT) 1.15; 95 % CI 1.03-1.28), rs7900150 (OR(AA) 1.23; 95 % 1.07-1.42), and rs1225404 (OR(CC) 0.82; 95 % 0.70-0.94).
|
23085767 |
2012 |